Liudmila Chernetska/iStock via Getty Images
- Johnson & Johnson (NYSE:JNJ) has submitted a marketing application to the U.S. FDA for the approval of icotrokinra.
- This treatment is intended for adults and children aged 12 and older who have moderate to severe plaque psoriasis.
- The submission is supported by a strong data that achieved all main goals in four phase 3 trials.